GPCR STRUCTURE
Crystal Structures of the Human ß2-Adrenergic G Protein-Coupled Receptor
Daniel Rosenbaum, Ph.D., Kobilka Lab, Department of Molecular and Cellular Physiology, Stanford University
Endogenous Agonist Mechanism for Activation of Class II GPCRs
Laurence Miller, M.D., Research, Mayo Clinic
SCREENING GPCRs
Use of Transiently Transfected Cells for Orphan Receptor Lead Discovery
Alice (Yu) Chen, Ph.D., Group Leader, Drug Discovery, Genomics Institute of Novartis Research Foundation (GNF)
Development and Application to Screening of Antibodies That Identify the Active State of G Proteins
Graeme Milligan, Ph.D., Professor of Molecular Pharmacology, University of Glasgow
High-Throughput Screening to Identify Modulators of GPCR Function
Stephen Rees, Director, Screening Compound Profiling UK, GlaxoSmithKline
GPCR-Targeted Compounds in Development
Macrocyclic Peptidomimetics: From a New Class of Conformationally-Restrained Molecules to the Discovery of Potent Modulators of Gastrointestinal Motility
Eric Marsault, Ph.D., Director, Medicinal Chemistry, Tranzyme Pharma Inc.
Histamine 3 Receptor Inverse Agonists for the Control of Food Intake and Beyond
Rosa Maria Rodriguez Sarmiento, Ph.D., Medicinal Chemistry, F. Hoffmann-La Roche Ltd.
Discovery of Agonists of the Niacin Receptor (GPR109a)
Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals